Research Papers:

Long non-coding RNA-CRNDE: a novel regulator of tumor growth and angiogenesis in hepatoblastoma

Rui Dong, Xiang-Qi Liu, Bin-Bin Zhang, Bai-Hui Liu, Shan Zheng and Kui-Ran Dong _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:42087-42097. https://doi.org/10.18632/oncotarget.14992

Metrics: PDF 2154 views  |   HTML 2175 views  |   ?  


Rui Dong1,*, Xiang-Qi Liu1,*, Bin-Bin Zhang1, Bai-Hui Liu1, Shan Zheng1 and Kui-Ran Dong1

1Department of Pediatric Hepatobiliary Surgery, Children’s Hospital of Fudan University, Key Laboratory of Neonatal Disease, Ministry of Health, Shanghai 201102, China

*Rui Dong and Xiang-Qi Liu have contributed equally to this work as first author

Correspondence to:

Rui Dong, email: [email protected]

Keywords: long non-coding RNA, tumor angiogenesis, tumor growth, mTOR signaling

Received: July 25, 2016    Accepted: January 10, 2017    Published: February 02, 2017


Long non-coding RNAs (lncRNAs) are involved in many biological processes, such as angiogenesis, invasion, cell proliferation, and apoptosis. They have emerged as key players in the pathology of several tumors, including hepatoblastoma. In this study, we elucidate the biological and clinical significance of CRNDE up-regulation in hepatoblastoma. CRNDE is significantly up-regulated in human hepatoblastoma specimens and metastatic hepatoblastoma cell lines. CRNDE knockdown reduces tumor growth and tumor angiogenesis in vivo, and decreases hepatoblastoma cell viability, proliferation, and angiogenic effect in vitro. Mechanistic studies show that CRNDE knockdown plays its anti-proliferation and anti-angiogenesis role via regulating mammalian target of rapamycin (mTOR) signaling. Taken together, this study reveals a crucial role of CRNDE in the pathology of hepatoblastoma. CRNDE may serve as a promising diagnostic marker and therapeutic target for hepatoblastoma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14992